Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30226% above fair value
$126.63+4.03 (+3.29%)
Close on Oct 30, 2026Market cap $10.53BP/E –Yield –
Earnings
Kymera Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
– on a year earlier
EPS, Q3 FY2026
-$1.32
-$0.94 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Kymera Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026before the open | – | – | -$1.32 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | $65.00M | +465.2% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026before the open | $34.40M | +55.7% | -$0.71 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $2.90M | -60.8% | -$0.97 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $2.80M | -24.3% | -$0.94 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | $11.50M | -55.3% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 9, 2025before the open | $22.10M | +114.6% | -$0.82 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $7.40M | -84.6% | -$0.88 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024before the open | $3.70M | -21.3% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024before the open | $25.70M | +55.8% | -$0.58 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $10.30M | +8.4% | -$0.69 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024before the open | $47.90M | +197.5% | -$0.25 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $4.70M | -51.0% | -$0.90 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $16.50M | +43.5% | -$0.67 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $9.50M | -1.0% | -$0.70 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023before the open | $16.10M | +5.2% | -$0.60 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $9.60M | -52.7% | -$0.79 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | $11.50M | – | -$0.78 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022before the open | $9.60M | – | -$0.71 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $15.30M | – | -$0.66 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | $20.30M | – | -$0.56 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 6, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Kymera Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Kymera Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Kymera Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- News
- News
- Update
- Update
- Results
- Update
- Results
- News